A phase 3, randomized, double-blinded, placebo-controlled study investigating the efficacy and safety of multiple dupilumab dose regimens administered as monotherapy for maintain treatment response in patients with atopic dermatitis

(PI: Rice, co-I: Chen) 1% effort 1 subject

Awarded By

  • Regeneron

Contributors

Amount

  • $17,545.00

Start/End

  • November 1, 2015 - 2017